Monday, April 22, 2019

Lilly taps Avidity's antibody-oligonucleotide conjugate tech in $35M deal



An interesting look at a different way to apply antibody conjugation to non-oncology based therapeutics.

https://www.fiercebiotech.com/biotech/lilly-taps-avidity-s-antibody-oligonucleotide-conjugate-tech-35m-deal

No comments:

Post a Comment